New RAPID Coverage Pathway Streamlines Medical Device Reimbursement

A collaborative effort between the Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) has introduced a new coverage pathway designed to streamline the reimbursement process for certain breakthrough medical devices. This initiative, known as the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, targets Class II and Class III breakthrough devices and aims to reduce the reimbursement timeline to approximately two months, significantly faster than the previous process, which could take a year or more.

Breakthrough devices, identified by the FDA, promise advanced treatment or diagnosis options for serious diseases, offering substantial improvements over existing solutions. This new voluntary program seeks to expedite the development, evaluation, and approval process for innovative medical devices, including those for conditions such as Alzheimer’s disease and innovative cancer detection technologies.

Innovators in the medtech industry often face substantial hurdles in securing Medicare coverage, a scenario that contributes to a funding shortfall often referred to as the "valley of death." Currently, many companies wait between five to seven years to obtain such coverage. With the introduction of the RAPID pathway, this wait time could potentially be cut to as little as two months, offering a more "predictable pathway for coverage," according to CMS.

Under the RAPID coverage pathway, CMS will simultaneously issue a proposed national coverage determination when an eligible device receives FDA market authorization. This triggers a 30-day public comment period as required by statute.

According to CMS Administrator Mehmet Oz, M.D., "FDA and CMS each play a critical role in getting new medical devices to patients, and they work most effectively when aligned sooner in that process." He added that the new pathway cuts red tape for innovators and enables Medicare beneficiaries to access groundbreaking medical technology more quickly.

The RAPID pathway is exclusive to FDA Breakthrough Devices addressing unmet medical needs for Medicare beneficiaries. Class II devices within the FDA Total Product Life Cycle Advisory Program (TAP) and Class III devices, even those outside of TAP participation, can qualify. Eligible devices must conduct investigational device exemption studies involving Medicare beneficiaries and align with clinical health outcomes determined by both agencies.

In implementing the RAPID coverage pathway, CMS and FDA have temporarily suspended the Transitional Coverage for Emerging Technologies Pathway for new entries. The effective date for the RAPID pathway will be decided following a 60-day public comment period on the final published notice.